Cetera Investment Advisers
IBRX icon

Cetera Investment Advisers’s ImmunityBio IBRX Stock Holding History

Cetera Investment Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.98M Buy
1,140,476
+193,767
+20% +$1.47M 0.01% 1156
2026
Q1 		$7.26M Buy
946,709
+910,062
+2,483% +$6.23M 0.01% 1273
2025
Q4 		$72.6K Buy
36,647
+11,813
+48% +$26.8K ﹤0.01% 4461
2025
Q3 		$61.1K Buy
24,834
+6,283
+34% +$16.2K ﹤0.01% 4407
2025
Q2 		$49K Buy
18,551
+6,731
+57% +$18.1K ﹤0.01% 3977
2025
Q1 		$35.6K Buy
+11,820
New +$35.8K ﹤0.01% 3882

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cetera Investment Advisers's IBRX Position: Q2 2026 in Review

Cetera Investment Advisers increased its ImmunityBio (IBRX) stake by 20% in Q2 2026, buying an estimated $1.47M and bringing the position to 1,140,476 shares worth $9.98M. The position accounts for 0.01% of the portfolio, ranked #1156.

Cetera Investment Advisers first reported a position in IBRX in Q1 2025 and has held it in 6 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Cetera Investment Advisers held 1,140,476 shares of ImmunityBio worth $9.98M as of Q2 2026.
  • Cetera Investment Advisers bought 193,767 ImmunityBio shares in Q2 2026, an estimated $1.47M.
  • ImmunityBio made up 0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #1156 holding.
  • Cetera Investment Advisers first reported a position in ImmunityBio in Q1 2025 and has held it in 6 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.